Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion on the potential of Lannett's (LCI) generic chemo agent temozolomide capsules to gain a portion of Merck's (MRK) market share for temodar in a certain type of brain tumor

Ticker(s): MRK, LCI

Who's the expert?

An expert with significant experience treating patients with this type of brain tumor who has deep knowledge of the labels, data, and profiles for temodar and temozolomide.

Interview Questions
Q1.

Can you describe your experience treating patients with this type of brain tumor and your knowledge of the labels, data, and profiles of temodar and temozolomide?

Added By: pjloria
Q2.

Are there any significant differences in the labels, data, and profiles for temodar and the generic capsul temozolomide? 

Added By: pjloria
Q3.

How many patients would you estimate are in the market for this particular type of brain tumor?

Added By: pjloria
Q4.

What are the pricing differences for temodar and temozolomide? 

Added By: pjloria
Q5.

What percentage of patients do you think will use temozolomide over temodar going forward? 

Added By: pjloria
Q6.

Why would a patient choose temodar over temozolomide? 

Added By: pjloria
Q7.

Is there potential for patients who are currently taking temodar to switch to temozolomide?

Added By: pjloria
Q8.

What obstacles will Lannett face in marketing temozolomide? 

Added By: pjloria

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Related Catalysts Image

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.